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Fumarate hydratase (FH) is a metabolic enzyme that converts
fumarate to malate. FH mutations predispose to a highly
aggressive and metastatic form of renal cancer. We have
recently shown that the accumulation of fumarate in
FH-deficient tumour drives an epigenetic reprogramming that
contributes to tumour invasiveness.
Cancer is a multifactorial disease thought to be driven by
genetic alterations. Mutations in metabolic enzymes of the
tricarboxylic acid (TCA) cycle, such as succinate dehydro-
genase (SDH), fumarate hydratase (FH) and isocitrate
dehydrogenase (IDH), lead to cancer, suggesting that altered
metabolism could play an active role in tumorigenesis.1 Our
laboratory studies howFH loss leads to renal cancer to dissect
the link between altered metabolism and cancer.
FH was originally found mutated in hereditary leiomyoma-
tosis and renal cell cancer (HLRCC),2 which causes a very
aggressive and metastatic type of renal cancer. It has been
proposed that fumarate, accumulated upon FH loss, con-
tributes to the molecular features of FH-deficient tumours,3
acting as an oncometabolite.1 For instance, fumarate
inhibits prolyl hydroxylases (PHD), α-ketoglutarate-dependent
dioxygenases (aKGDD) involved in HIF degradation, leading
to HIF stabilisation and pseudohypoxia.4 Through covalent
bonding with reactive thiol residues of Keap1, fumarate was
also shown to activate a potent antioxidant responsemediated
by NFE2-related factor 2 (NRF2).1 More recently, it was found
that fumarate could also inhibit Ten-Eleven Translocation
(TET) proteins, another class of aKGDDs involved in DNA
demethylation,5,6 leading to DNA hypermethylation. The role
of this epigenetic alteration in tumorigenesis is still unclear. In
our recent work,7 we have shown that, by virtue of its
epigenetic function, fumarate contributes to the invasive
features of FH-deficient renal cancers.
Using proteomics and transcriptomics analyses, we demon-
strated that epithelial mouse and human FH-deficient renal
cells exhibit overlapping mesenchymal features. Further
functional characterisation revealed that the loss of FH
activates an epithelial-to-mesenchymal transition (EMT), a
process involved in both tumour initiation and progression.8
EMT is orchestrated by various transcription factors that
suppress epithelial genes and activate mesenchymal
markers. To investigate how the loss of FH could activate
EMT, we measured the expression of several EMT-related
transcription factors. We showed that Fh1-deficient cells
express high levels of Zeb1 and Zeb2 and that miR-200, a
family of miRNAs that suppresses Zeb translation, were
strongly downregulated in these cells. It was recently
shown9,10 that miR-200 expression is regulated by promoter
methylation, which, in turn, is controlled by TET demethylating
activity. We therefore hypothesised that the epigenetic
suppression of miRNA 200 could be caused by fumarate-
driven inhibition of TET. In linewith this hypothesis, we showed
that a regulatory region of mir200ba429 cluster is hyper-
methylated in Fh1-deficient cells. Importantly, the epigenetic
and phenotypic changes caused by FH loss were recapitulated
by the incubation of Fh1-proficent cells with cell-permeable
fumarate (see Figure 1 for a schematic of the pathway). These
results showed, for the first time, that fumarate triggers EMT
via the epigenetic suppression of miR-200.
The link between fumarate accumulation and EMTwas also
validated in renal cancer samples. First, we found that HLRCC
patients exhibited a significant increase in fumarate levels,
inhibition of TETactivity, and miR-200 suppression compared
to adjacent normal tissue. Then, taking advantage of the data
from The Genome Cancer Atlas (TGCA), we found that FH
loss resulted in hypermethylation and suppression of miR-200
in a larger cohort of FH-deficient renal cancers. Finally, we
found that FH is downregulated in a set of clear cell renal cell
carcinoma, and FH expression is positively correlated to EMT
markers, confirming the link between FH and EMT in vivo in
hereditary and sporadic tumours.
Although fumarate accumulation activates a plethora of
signalling cascades, our findings suggest that the EMT is a key
phenotype of FH-deficient cancer driven caused by fumarate-
driven TET-mediated suppression of miR-200. This unex-
pected property of fumarate is likely shared by other
oncometabolites. Indeed, both succinate and 2-hydroxygluta-
rate, the metabolites accumulated in SDH and IDH mutant
tumours, respectively, are also well-established TET inhibi-
tors. Interestingly, SDH-deficient pheochromocytomas and
paragangliomas,11 Sdhb-deficient cells,7 and IDH-mutant
cells also exhibit EMT.12 Our results indicate that, at least in
Sdhb-deficient cells, EMT induction is mediated by epigenetic
suppression of miR-200, similar to that observed in FH-
deficient cells. These results have important implications.
First, they indicate that TET inhibition and EMT induction could
be a convergent mechanism of action of these metabolites.
Second, they suggest that EMT could be a common response
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to loss of mitochondrial enzymes and could link mitochondrial
dysfunction to tumorigenesis. It is tempting to speculate that
environmental conditions that affect mitochondrial function
and, as a consequence, the abundance of TCA cycle
metabolites, such as ischaemia or hypoxia, could also lead
to dysregulation of TET activity, promoting tumorigenesis. In
conclusion, our findings go beyond the understanding of how
FH mutations lead to HLRCC and pave the way for the
understanding of how mitochondrial metabolites could
promote tumorigenesis.
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Figure 1 Schematic representation of the proposed link between FH loss and EMTactivation. Left panel: In epithelial Fh1-proficient cells, TETs bind the mir-200 regulatory
region, favouring DNA demethylation and miR-200 expression. miR-200 can then bind its mRNA targets such as Zeb1, efficiently reducing Zeb1 translation. Right panel: After FH
loss, fumarate is accumulated and inhibits TETs activity, leading to mir-200 DNA hypermethylation. The reduced expression of miR-200 favours Zeb1 translation and subsequent
EMT reprogramming. Cells switch their phenotype, moving from an epithelial to a mesenchymal configuration
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